{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/chickenpox/how-up-to-date-is-this-topic/changes/","result":{"pageContext":{"chapter":{"id":"10059b43-4a23-59cf-8f5f-31f8d5e8e3c9","slug":"changes","fullItemName":"Changes","depth":2,"htmlHeader":"<!-- begin field abfa308c-7b2c-49c2-841d-cd0e3f013efc --><h2>Changes</h2><!-- end field abfa308c-7b2c-49c2-841d-cd0e3f013efc -->","summary":null,"htmlStringContent":"<!-- begin item 2cecde72-f97f-4e55-aade-1a7270fc9f42 --><!-- begin field 7fabd828-7971-4725-81e2-bc8eb0abebcc --><p><strong>August 2018 </strong>— minor update. The recommendation to notify relevant authorities in Scotland and Northern Ireland has been removed as chickenpox is no longer a notifiable disease. </p><p><strong>September 2017 </strong>— minor update. Typographical error corrected. </p><p><strong>September to October 2016 </strong>— reviewed. A literature search was conducted in September 2016 to identify evidence-based guidelines, UK policy, systematic reviews, and key RCTs published since the last revision of the topic. Changes include:</p><ul><li>Nonsteroidal anti-inflammatory drugs are no longer recommended as a symptomatic treatment option because of evidence of an increased risk of adverse skin reactions in children with chickenpox.</li><li>Minor amendments to the recommendations on the management of neonates with chickenpox.</li><li>Amendments to the breastfeeding management section to recommend seeking specialist advice before prescribing aciclovir.</li><li>Minor amendments to clarify that the infectious period and duration of chickenpox may be prolonged in an immunocompromised person.</li><li>Minor amendments to the recommendations on managing healthcare workers and immunocompromised people who have been exposed to chickenpox.</li><li>Restructuring of the prescribing information section and inclusion of prescribing information on chlorphenamine.</li></ul><!-- end field 7fabd828-7971-4725-81e2-bc8eb0abebcc --><!-- end item 2cecde72-f97f-4e55-aade-1a7270fc9f42 -->","topic":{"id":"5d1b7a44-f7ff-52e9-a218-c53ecadb0e4c","topicId":"4960f8a4-0140-4c3b-9bd0-b1ac6fccd648","topicName":"Chickenpox","slug":"chickenpox","lastRevised":"Last revised in August 2018","chapters":[{"id":"fe0450ab-ddfd-5960-bb47-b986d9cc6059","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"ff90f80f-13d4-5732-8d09-9c5566ce6ec2","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"16ae9969-1384-5b7b-aff0-1ac19aeee530","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"10059b43-4a23-59cf-8f5f-31f8d5e8e3c9","slug":"changes","fullItemName":"Changes"},{"id":"5f0098ae-9d37-5658-9379-66477733f220","slug":"update","fullItemName":"Update"}]},{"id":"9d70228e-0283-5d34-a4af-5237097d0a02","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"fa1d46ea-9d63-5d1a-b60c-9b96e87f802c","slug":"goals","fullItemName":"Goals"},{"id":"4e21e939-92fd-555c-a175-93b8a626169a","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"ea18d1e8-0bdd-542f-a985-2952ecabca2d","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"5d911096-5b50-551b-a17a-cff3070315b0","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"601f7c68-386e-5474-96f1-d6239bd81750","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"305e8fa8-8eb6-5b69-a902-93019e0c2c17","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"bb9b11dc-3295-5e2b-9798-37bb8b6ebbc0","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"145f102c-4e0f-52c9-8b3b-e0b5c6eb112e","slug":"definition","fullItemName":"Definition"},{"id":"9f4d0cad-78a8-568f-831e-8878d2f4bfd3","slug":"transmission","fullItemName":"Transmission"},{"id":"5691920a-f618-5a98-ab32-417dfc782db1","slug":"prevalence","fullItemName":"Prevalence"},{"id":"eb6a66b5-2006-5968-a97d-52de72842cbf","slug":"complications","fullItemName":"Complications"}]},{"id":"a3eb8e9b-cdd9-5243-8353-09aac3fdc322","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"ff9f70a8-0c29-5357-946d-bbca67eafbbf","slug":"diagnosis","fullItemName":"Diagnosis"},{"id":"b651c5b4-34df-5480-b05d-909c9023a7a5","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"3844af91-e26b-515e-a645-9725d2f54810","fullItemName":"Management","slug":"management","subChapters":[{"id":"7700c175-994a-51d5-a2d0-36eb7478e2c1","slug":"child-or-adult","fullItemName":"Scenario: Child or adult"},{"id":"f6a62aa2-354d-5eee-a868-fb5d162115ef","slug":"pregnant-woman","fullItemName":"Scenario: Pregnant woman"},{"id":"c659257f-8875-5440-ae24-57c071cf226c","slug":"breastfeeding-woman","fullItemName":"Scenario: Breastfeeding woman"},{"id":"499e6045-af39-5bc4-952b-edcb6b29144f","slug":"neonate","fullItemName":"Scenario: Neonate"},{"id":"dac00668-b032-569c-8b5a-260c2f1625b3","slug":"immunocompromised","fullItemName":"Scenario: Immunocompromised"},{"id":"072ae3a5-9cf4-5233-bca1-2d46e53de42b","slug":"exposure-to-chickenpox","fullItemName":"Scenario: Exposure to chickenpox"}]},{"id":"fa12b54d-0c95-5ee8-8884-219ac7a9dd2a","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"a2d64426-afb7-5590-998d-3ed0d13b78d2","slug":"chlorphenamine","fullItemName":"Chlorphenamine"},{"id":"17d5cf92-3449-52d5-932c-f1b770061787","slug":"aciclovir","fullItemName":"Aciclovir"}]},{"id":"95550d9e-6be2-5a94-924a-c4c2f8e7dbe4","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"880099bb-bff8-543e-a1e8-267413ef45b9","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"c80905f1-b771-5170-8be8-c1bcee935552","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"6bf66548-b486-53e1-bce7-d9bb45af9bea","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"52168b40-dab0-5afb-9662-bb28014b5734","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"5fa2da47-e83a-5886-9c1b-c6ae4e97a0a7","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"769ea126-78ac-540c-a1c9-38446d44e22e","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"87e1772a-0cd8-5e0c-ad7a-b676a65171bb","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"16ae9969-1384-5b7b-aff0-1ac19aeee530","slug":"how-up-to-date-is-this-topic","fullItemName":"How up-to-date is this topic?"},"subChapters":[{"id":"e28c2bcb-e886-5b75-8c75-533b8950bc64","slug":"previous-changes","fullItemName":"Previous changes","depth":3,"htmlHeader":"<!-- begin field 465238ce-73cf-4e98-b50a-0d520d52d5cf --><h3>Previous changes</h3><!-- end field 465238ce-73cf-4e98-b50a-0d520d52d5cf -->","summary":null,"htmlStringContent":"<!-- begin item ff684829-7f5b-4065-8605-244b2fb5eb03 --><!-- begin field 148964c2-3755-488b-b24c-c32f764179b4 --><p><strong>June 2015 </strong>—<strong> </strong>minor update. Based on an update to the manufacturer's Summary of Product Characteristics (SPC) for Zovirax<sup>® </sup>suspension:</p><ul><li>Rare hereditary problems of fructose intolerance has been added as a contraindication to the use of aciclovir suspension.</li><li>Allergic reactions (possibly delayed) has been added as a possible adverse effect of aciclovir suspension.</li></ul><p><strong>September 2014 </strong>— minor update to the prescribing section for NSAIDs to reflect the fact that severe skin complications are associated with NSAIDs when taken by children with varicella.</p><p><strong>February 2013 </strong>— minor update. The 2013 QIPP options for local implementation have been added to this topic.</p><p><strong>November 2012 </strong>— reviewed. A literature search was conducted in September 2012 to identify evidence-based guidelines, UK policy, systematic reviews, and key RCTs published since the last revision of the topic. No changes to clinical recommendations have been made.</p><p><strong>October 2012 </strong>— minor update. The 2012 QIPP options for local implementation have been added to this topic.</p><p><strong>July 2011 </strong>— minor update. More exact paracetamol dosing for children has been introduced by the Medicines and Healthcare products Regulatory Agency. Prescriptions have been updated to reflect the revised dosing. Issued in July 2011.</p><p><strong>May 2011 </strong>— minor update. The 2010/2011 QIPP options for local implementation have been added to this topic. Issued in June 2011.</p><p><strong>March 2011 </strong>— topic structure revised to ensure consistency across CKS topics — no changes to clinical recommendations have been made.</p><p><strong>October 2010 </strong>— minor update. Generic chlorphenamine is no longer licensed for the treatment of pruritus. Text and prescriptions amended to reflect this. Issued in October 2010.</p><p><strong>August 2010 </strong>— updated to include advice from the Health Protection Agency and Association of Medical Microbiologists on considering treatment with aciclovir in adolescents aged 14 years and older if they present within 24 hours of the start of the rash. Issued in September 2010.</p><p><strong>March 2010 </strong>— updated to include advice on considering whether bacterial superinfection is complicating chickenpox, particularly in people with eczema. Issued in March 2010.</p><p><strong>August 2007 to January 2008 </strong>— converted from CKS guidance to CKS topic structure. The evidence-base has been reviewed in detail, and recommendations are more clearly justified and transparently linked to the supporting evidence. There have been changes to the recommendations regarding symptomatic treatment, antiviral treatment for otherwise healthy adults, and management of chickenpox in a breastfeeding woman.</p><p><strong>October 2006 </strong>— minor update. Analgesia prescriptions updated because new doses of ibuprofen for children are recommend by the British National Formulary. Issued in October 2006.</p><p><strong>October 2005 </strong>— minor technical update. Issued in November 2005.</p><p><strong>April 2004 </strong>— reviewed. Validated in September 2004 and issued in November 2004.</p><p><strong>January 2002 </strong>— reviewed. Validated in March 2002 and issued in April 2002.</p><p><strong>July 1998 </strong>— written.</p><!-- end field 148964c2-3755-488b-b24c-c32f764179b4 --><!-- end item ff684829-7f5b-4065-8605-244b2fb5eb03 -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}